U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016

Joshua D. Wallach; Taeho Greg Rhee; E. Jennifer Edelman; Nilay D. Shah; Stephanie S. O’Malley; Joseph S. Ross

doi:10.1007/s11606-021-06668-x

U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016

Joshua D. Wallach, Taeho Greg Rhee, E. Jennifer Edelman, Nilay D. Shah, Stephanie S. O’Malley, Joseph S. Ross

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	495-498
Number of pages	4
Journal	Journal of general internal medicine
Volume	37
Issue number	2
DOIs	https://doi.org/10.1007/s11606-021-06668-x
State	Published - Feb 2022

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1007/s11606-021-06668-x

Cite this

@article{a0f546fad7da4b47a032dfec389c4ecf,

title = "U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016",

author = "Wallach, {Joshua D.} and Rhee, {Taeho Greg} and Edelman, {E. Jennifer} and Shah, {Nilay D.} and O{\textquoteright}Malley, {Stephanie S.} and Ross, {Joseph S.}",

note = "Funding Information: Research reported in this publication was supported by the National Institue on Alcohol Abuse and Alcoholism of the National Istitutes of Health under the award number K01AA028258 (Dr. Wallach). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content of this article is soley the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: In the past 36 months, Dr. Wallach received research support through the Collaboration for Research Integrity and Transparency (CRIT) at Yale University from the Laura and John Arnold Foundation and through the Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938). Dr. Rhee was supported in part by the National Institute on Aging (#T32AG019134) through Yale School of Medicine in the past 36 months. Rhee is currently funded by the National Institute of Mental Health (#R21MH117438) and the Institute for Collaboration on Health, Intervention, and Policy (InCHIP) at the University of Connecticut. In the past 36 months, Dr. Edelman has received research support through the NIH (National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and National Institute of Mental Health (NIMH)). In the past 36 months, Dr. Shah has received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938) and through National evaluation center for health technologies (NESTcc) from the Food and Drug Administration; the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet). Dr. O{\textquoteright}Malley reports having been a consultant or advisory board member for Alkermes, Amygdala, Dicerna, and Opiant, a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative (ACTIVE) supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka; receiving donated study medications for NIH sponsored research from Astra Zeneca, Novartis; DSMB Member for NIDA Clinical Trials Network (Emmes). Dr. Ross received research support through Yale from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the FDA to establish a Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Agency for Healthcare Research and Quality (R01HS022882). ",

year = "2022",

month = feb,

doi = "10.1007/s11606-021-06668-x",

language = "English (US)",

volume = "37",

pages = "495--498",

journal = "Journal of General Internal Medicine",

issn = "0884-8734",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits

T2 - NAMCS 2014 to 2016

AU - Wallach, Joshua D.

AU - Rhee, Taeho Greg

AU - Edelman, E. Jennifer

AU - Shah, Nilay D.

AU - O’Malley, Stephanie S.

AU - Ross, Joseph S.

N1 - Funding Information: Research reported in this publication was supported by the National Institue on Alcohol Abuse and Alcoholism of the National Istitutes of Health under the award number K01AA028258 (Dr. Wallach). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content of this article is soley the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: In the past 36 months, Dr. Wallach received research support through the Collaboration for Research Integrity and Transparency (CRIT) at Yale University from the Laura and John Arnold Foundation and through the Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938). Dr. Rhee was supported in part by the National Institute on Aging (#T32AG019134) through Yale School of Medicine in the past 36 months. Rhee is currently funded by the National Institute of Mental Health (#R21MH117438) and the Institute for Collaboration on Health, Intervention, and Policy (InCHIP) at the University of Connecticut. In the past 36 months, Dr. Edelman has received research support through the NIH (National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and National Institute of Mental Health (NIMH)). In the past 36 months, Dr. Shah has received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938) and through National evaluation center for health technologies (NESTcc) from the Food and Drug Administration; the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet). Dr. O’Malley reports having been a consultant or advisory board member for Alkermes, Amygdala, Dicerna, and Opiant, a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative (ACTIVE) supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka; receiving donated study medications for NIH sponsored research from Astra Zeneca, Novartis; DSMB Member for NIDA Clinical Trials Network (Emmes). Dr. Ross received research support through Yale from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the FDA to establish a Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Agency for Healthcare Research and Quality (R01HS022882).

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85124051359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124051359&partnerID=8YFLogxK

U2 - 10.1007/s11606-021-06668-x

DO - 10.1007/s11606-021-06668-x

M3 - Article

C2 - 33674920

AN - SCOPUS:85124051359

SN - 0884-8734

VL - 37

SP - 495

EP - 498

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

IS - 2

ER -

U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this